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Abstract 
The Dean and Betty Gallo Prostate Cancer Center (GPCC) was established with the goal of eradicating prostate 
cancer and improving the lives of men at risk for the disease through research, treatment, education and 
prevention. GPCC was founded in the memory of Dean Gallo, a beloved New Jersey Congressman who died 
tragically of prostate cancer diagnosed at an advanced stage. GPCC unites a team of outstanding researchers 
and clinicians who are committed to high-quality basic research, translation of innovative research to the clinic, 
exceptional patient care, and improving public education and awareness of prostate cancer. GPCC is a center of 
excellence of The Cancer Institute of New Jersey, which is the only NCI-designated comprehensive cancer 
center in the state. GPCC efforts are now integrated well as part of our Prostate Program at CINJ, in which Dr. 
Robert DiPaola and Dr. Cory Abate-Shen are co-leaders. 
The Prostate Program unites 19 investigators fiom 10 academic departments who have broad and 
complementary expertise in prostate cancer research. The overall goal and unifying theme is to elucidate basic 
mechanisms of prostate growth and oncogenesis, with the ultimate goal of promoting new and effective 
strategies for the eradication of prostate cancer. Members' wide range of research interests collectively 
optimize the chances of providing new insights into normal prostate biology and unraveling the molecular 
pathophysiology of prostate cancer. Cell culture and powerful animal models developed by program members 
recapitulate the various stages of prostate cancer progression, including prostatic intraepithelial neoplasia, 
adenocarcinoma, androgen-independence, invasion and metastases. These models promise to further strengthen 
an already robust program of investigator-initiated therapeutic clinical trials, including studies adopted by 
national cooperative groups. Efforts to translate laboratory results into clinical studies of early detection and 
chemoprevention are underway. 
The specific goals of this program are: 
1. 
2.  
3. 
To investigate the molecular mechanisms underlying normal prostate growth and differentiation and 
elucidate the molecular mechanisms underlying prostate oncogenesis. 
To build on fundamental knowledge to develop effective therapeutic approaches for the treatment of 
prostate cancer. 
To improve the control of prostate cancer through early detection, chemoprevention, and outreach and 
education. 
This new disease-based program is structured to improve interdisciplinary interactions and translational results. 
Already, through the dynamic leadership of Drs. Cory Abate-Shen and Robert DiPaola, new investigators were 
attracted to the field, new collaborations engendered, and numerous investigator-initiated trials implemented. 
Progress in GPCC and the program overall has been outstanding. The Center has success in uniting 
investigators with broad and complementary expertise in prostate cancer research. The overall goal and 
unifying theme is to elucidate basic mechanisms of prostate growth and oncogenesis, with the ultimate goal of 
promoting new and effective strategies for the eradication of prostate cancer in patients and populations at risk. 
Members' wide range of research interests collectively optimize the chances of providing new insights into 
normal prostate biology and unraveling the molecular pathophysiology of prostate cancer. Studies in cell culture 
and powerful animal models developed recapitulate the various stages of prostate cancer progression, including 
prostatic intraepithelial neoplasia, adenocarcinoma, androgen-independence, invasion and metastases. These 
* ’ models promise to further strengthen an already robust program of investigator-initiated therapeutic clinical 
trials, including studies adopted by national cooperative groups. Efforts to translate laboratory results into 
clinical studies of early detection and chemoprevention are underway. 
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Scientific Goals 
GPCC and the program overall has success in uniting investigators with broad and complementary espertise in 
prostate cancer research. The Prostate Program unites investigators with broad but complementary expertise in 
prostate cancer research. The overall goal and unifying theme is to elucidate basic mechanisms of prostate 
development and oncogenesis, with the ultimate goal of promoting new and effective strategies for the 
eradication of prostate cancer. Members have a wide range of research interests that collectively optimize the 
chances of providing new insights into normal prostate biology, as well as unraveling the molecular 
pathophysiology of prostate cancer. Studies in cell culture systems and animal models recapitulate the various 
stages of prostate cancer progression, including prostatic intraepithelial neoplasia, adenocarcinoma, androgen- 
independence, invasion and metastases. These models promise to strengthen the already robust menu of 
investigator-initiated therapeutic and preventive clinical trials, including studies adopted by national cooperative 
group. Efforts to tranlate laboratory results into clinical studies of early detection and chemoprevention are 
underway. 
The specific goals of this program are: 
1. To investigate the molecular mechanisms underlying normal prostate growth and differentiation and 
2. To build on fundamental knowledge to develop effective therapeutic approaches for the treatment of 
3. To improve the control of prostate cancer through early detection, chemoprevention, outreach and 
elucidate the molecular mechanisms leading to prostate cancer. 
prostate cancer. 
education. 
Scientific Accomplishments 
Members of the Prostate Program made important contributions in each of the main focus areas. These 
accomplishments are summarized below. 
1. To investigate the molecular mechanisms underlying normal prostate growth and differentiation and 
elucidate the molecular mechanisms leading to prostate cancer. 
RATIONALEKANCER FOCUS: Through a fundamental understanding of prostate biology gleaned from a 
combination of in vivo and in vitro approaches, program members are making important inroads into 
understanding the pathways of prostate cancer initiation and progression. One of the principal accomplishments 
of the Prostate Program is the generation of new mouse models of prostate cancer. These models stimulated a 
broad range of multidisciplinary studies on the mechanisms of prostate cancer development, the elucidation of 
molecular events associated with disease progression, and have the potential for developing new paradigms for 
prevention and treatment. Summarized below are examples of these research accomplishments. 
ACCOMPLISHMENTS: The collaborative efforts of Cory Abate-Shen and Michael Shen elucidated a critical role 
for the Nkx3. I homeobox gene in the development of the normal prostate and how defects in its expression 
contribute to the development of prostate cancer. GPCC has supported the development of the transgenic 
mouse core facility at CINJ. They demonstrated that Nkx3. I is the earliest known marker of prostate formation 
and that it is required for appropriate prostate morphogenesis and epithelial differentiation. These studies were 
accelerated by their creation of mutant mice with loss-of-function of Nkx3.1. Using transcriptional profiling of 
normal and mutant mouse tissues, they are uncovering the mechanisms by which Nkx3. I regulates prostatic 
epithelial differentiation. For example, they found that Nkx3. I mutants express genes that are usually restricted 
to seminal vesicles, suggesting that loss-of-function of Nh3.1  leads to defects in prostatic epithelial 
specification. They hypothesized that these defects in specification predispose Nkx3. I mutant mice to malignant 
transformation of the prostate. These studies provide important insights linking the control of differentiation to 
mechanisms underlying oncogenesis, as well as the role of homeobox genes in these processes (Abate-Shen, 
Nut Rev Cancer, 2002; Abate-Shen, Cancer Cell, 2003; Shen and Abate-Shen, Dev Dyn, 2003). 
Shen applied his expertise in vertebrate development using mouse models (Ding et al., Nature, 1998; Yan et al., 
Genes Dev, 1999; Schier and Shen, Nature, 2000; Iratni et al., Science, 2002; Morkel et al., Development, 2003; 
Shen, J Clin Invest, 2003) to the study of prostate biology (Bhatia-Gaur et al., Genes Dev, 1999). He generated 
mice carrying an Nkx3. I-lac2 knock-in allele, which enabled him to develop a novel explant culture system that 
supports the reproducible growth and differentiation of prostatic epithelium in vitro (Dev. Bio., 2003, in press). 
Dr. Shen and colleagues used this assay to quantify the formation of prostatic ducts in explant cultures using 
embryonic tissues that normally give rise to prostate from wild-type and mutant mice. This assay can be adapted 
for rapid screening of therapeutics agents that affect prostatic growth. In collaboration with Dr. Philip Beachy’s 
laboratory at John’s Hopkins, they found that inhibition of sonic hedgehog (Shh) signaling had adverse 
consequences for prostate morphogenesis. Their studies also demonstrated that defects in prostate 
morphogenesis in Shh mutants is an indirect consequence of a partial deficiency in androgen production; Shh 
a 
5 does not appear to be essential for prostate induction, but is required for prostate morphogenesis. Given the 
importance of aberrant Shh signaling in other cancers, these findings suggest a role for this signaling pathway in 
the genesis of prostate cancer. 
Signaling through the insulin-like growth factor (IGF) pathway became an entry point for John Pintar into 
prostate cancer research. Pintar investigates the role of IGF binding proteins (IGF-BPs) in normal growth and 
development using mutant mouse models generated in his laboratory (Pintar et al., Prog Growth Factor Res, 
1995; Pintar et al., Horm Res, 1996; Grewal et al., Horm Metab Res, 1999; Wood et al., Mol Endocrinol, 2000; 
Nitsche et al., J Neurosci, 2002; Clarke et al., Neuroscience, 2003; Nitsche and Pintar, Dev Biol, 2003). Inspired 
by work of others, who had shown that serum levels of IGF were linked to prostate cancer risk in humans, he 
applied for and received funding from CINJ Developmental Funds to explore the consequences of loss-of- 
function of IGF-BPs in prostate cancer. He found that IGF-BP mutant mice displayed hyperplasia and dysplasia 
of the prostate that was consistent with a pre-cancerous phenotype. He is now investigating whether this 
phenotype can be exacerbated by combinatorial mating with prostate-cancer-prone strains, such as p53, Pten, 
and Nkx3. I through collaborations with Abate-Shen and other program members. 
Understanding androgen-mediated signal transduction is essential to our knowledge of basic prostate biology 
and to the pathophysiology of prostate cancer. Joseph Fondell was newly recruited to the faculty and to the field 
of prostate cancer research to apply his expertise on androgen receptor (AR) physiology to the study of prostate 
cancer. His laboratory developed a unique series of cell lines that express an epitope-tagged AR to isolate 
interacting proteins that are likely to regulate transcriptional activity (Wang and Fondell, Anal Biochem, 2001 ; 
Sharma and Fondell, Proc Natl Acad Sci U S  A, 2002; Zhang et al., Oncogene, 2002). Dr. Fondell demonstrated 
that AR interacts with the T W M e d i a t o r  protein, which was first identified as a transcriptional co-activator 
for another nuclear hormone transcription factor (Sharma and Fondell, Proc Natl Acad Sci U S  A, 2002). Using 
chromatin immunoprecipitation assays to define interactions with chromatin templates in cell culture, he found 
that components of the TRAP complex interact with AR on androgen-responsive promoters in LNCAP prostate 
cancer cells. Fondell is testing the hypothesis that one of the mechanisms underlying the transition from 
androgen-dependence to androgen-independence in prostate cancer involves the potential of AR to associate 
with distinct protein complexes in androgen-responsive versus non-responsive cells. He is collaborating with 
Danny Reinberg to investigate chromatin assembly in prostate cancer, and with Shen to develop mice having 
epitope-tagged versions of AR to investigate AR-associated proteins in vivo as a function of prostate cancer 
progression. 
Reinberg, an international leader in the field of transcriptional regulation, recently embarked on prostate cancer 
research through his interest in factors that alter chromatin structure and regulate gene expression (Kuzmichev 
et al., Genes Dev, 2002; Nishioka et al., Genes Dev, 2002; Nishioka et al., Mol CeZl, 2002; Belotserkovskaya et 
al., Science, 2003; Fried1 et al., Proc Natl Acad Sci U S A ,  2003; Saunders'et al., Science, 2003). His laboratory 
isolated PRC2 from HeLa cells and found that it methylated lysine-27 on the histone H3 tail. They found that 
the enzymatic activity of PRC2 resides in a polypeptide termed Enhancer of Zeste (Ezh2). Ezh2, like most other 
histone lysine methyltransferases (HKMTs), PRC2 contains a SET domain that is an evolutionarily conserved 
sequence motif identified in the Drosophila PEV (position effect variegation) suppressor SU(VAR)3-9, the 
Polycomb-group protein Enhancer of Zeste, and the trithorax-group protein Trithorax. Work Reinberg and 
others demonstrated that this class of protein establish a restrained state of transcriptional repression during 
development, whereas perturbations of this system can have profound consequences for cancer cells. Reinberg 
became interested in the potential role of Ezh2 in prostate cancer based on studies reported by others in which 
gene expression profiling revealed a correlation of Ezh2 expression and the development of prostate cancer. He 
is collaborating with Dr. Shen to develop mutant mouse models for Ezh2 to investigate its role in the 
development of prostate cancer. Dr. Reinberg, working in collaboration with Abate-Shen, recently found that 
Ezh2 overexpression is inversely correlated with methylation of lysine-27 in prostate tissues. These data have 
important implications for the mechanisms by which Ezh2 contributes to prostate cancer. 
. 
% Activation of the transcription factor NF-KB leads to expression of several genes and an array of biological 
consequences including resistance to apoptosis and stimulation of cell proliferation. Arnold Rabson received 
GPCC Developmental Funds to apply his expertise in this areas to the study of prostate cancer. In collaboration 
with Celine Gelinas (Transcriptional Regulation and Oncogenesis Program), they found that NF-KB is 
constituitively activated in androgen-independent prostate cancer cells but not in androgen-dependent cell lines. 
Evidence of nuclear localization of NF-KB protein, indicative of activation, was also identified in tumor tissue 
samples of intermediate-grade prostate adenocarcinoma obtained through the CINJ Tissue Retrieval Service 
(Suh et al., Prostate, 2002). Studies in Rabson’s laboratory are currently directed at defining the mechanisms 
responsible for constitutive activation of NF-KB and the consequences of this activation for the development 
and treatment of prostate cancer. He is collaborating with clinical scientists to develop therapeutic approaches to 
inactivate NF-KB in several forms of malignancy including prostate cancer. 
Ramsey Foty developed novel explant assays to investigate how the biophysical properties of prostate cells 
correlate with their invasive potential. He used tissue surface tensiometry (TST), a novel in vitro method that 
measures elasticity, viscosity, and cohesivity (Dugay et al., Dev Biol, 2003; Robinson et al., J.  Cell Sci, 2003; 
Ryan et al., Proc Natl Acad Sci USA, 2001; Foty and Steinberg, Int JDev  Biol, 2004a; Robinson et al, Mol Biol 
Cell, 2004; Winters et al., Int J Cancer, 2004). For comprehensive reviews see Foty and Steinberg, Int J. Dev 
Biol, 2004a and 2004b. They compared normal and malignant prostate to determine whether TST is an 
accurate predictor of the invasive potential of prostate tumors, how changes in the tumor microenvironment 
influence biophysical and invasive properties, and how changes in stromal components, including smooth 
muscle cells and fibroblasts, influence the elastic and viscous properties of tumors. Foty’s lab demonstrated that 
invasive behavior of prostate carcinoma cell lines is correlated with tumor cohesivity as measured by TST (Foty 
et al., Surgical Forum, 1999). They also established a 3D in vitro co-culture system used to investigate the 
degree and rate of compaction of invasive cancer cells. They demonstrated that the degree of compaction is 
correlated with increased aggregate cohesivity as measured by TST. These assays are being adapted for rapid 
and quantitative approaches to address how potential therapeutic agents affect the biophysical properties of 
prostate cancer cells, and thereby affect invasive potential. 
In the burgeoning field of gene therapy, a major limitation is the ability to control delivery of therapeutic genes 
specifically to cancer cells, since these vectors are often designed to produce cell death. Monica Roth’s 
laboratory established a novel approach to the design of retroviral vectors for specific delivery into prostate 
cancer (Bupp and Roth, Mol Ther, 2002; Bupp and Roth, Hum Gene Ther, 2003). She is taking advantage of the 
fact that retroviral entry into cells is controlled by the surface envelope (Env) protein, which can be altered by 
replacement of a ten amino acid peptide sequence in the cell-targeting region. By screening libraries of 
retroviral Env proteins with random peptides substituted into this region, she identified novel Env isolates that 
efficiently deliver a gene to PC-3 human prostate tumor cells. These “designer” Env proteins will be important 
reagents in the development of gene therapy for prostate cancer and other malignancies. 
E 
Abate-Shen and Shen developed a series of mouse models that recapitulate the stages of prostate epithelial 
transformation (Bhatia-Gaur et al., Genes Dev, 1999; Abate-Shen and Shen, Genes Dev, 2000; Abate-Shen, Nat 
Rev Cancer, 2002; Abate-Shen and Shen, Trends Genet, 2002; Kim et al., Cancer Res, 2002; Kim et al., Proc 
Natl Acad Sci U S  A, 2002; Abate-Shen et al., Cancer Res, 2003). Their efforts were accelerated through a grant 
from the Mouse Models of Human Cancer Consortium. These models are based on the loss-of-function of three 
genes implicated in human prostate cancer; the Nkx3.1 homeobox gene, the Pten tumor suppressor gene, and the 
~ 2 7 ~ ’ ” ‘  cell-cycle regulatory gene. Nkx3.J single-mutant mice provide a model for prostate cancer initiation and 
were used to develop a novel assay to investigate the precursor-product relationship of prostate intraepithelial 
neoplasia (PIN) to cancer (Bhatia-Gaur et al., Genes Dev, 1999; Kim et al., Cancer Res, 2002). These mutant 
mice provided important insights into the molecular mechanisms underlying the earliest stages of prostate 
cancer development and give investigators access to tissues that are difficult to consistently obtain from 
humans. These models display features of the human disease and provide insights into prostate cancer 
causation. For example, Abate-Shen and Shen recently found that loss-of-function of N h 3 .  I leads to increased 
' oxidative damage to prostatic epithelium as a function of aging. Therefore, Nkx3. I mutants provide a model to 
study the consequences and prevention of oxidative damage with naturally occurring antioxidants. During the 
next grant period this approach will be carried out in collaboration with Jeffiey Laskin and members of the 
Carcinogenesis and Chemoprevention Program. 
By breeding compound mutant mice with loss-of-function of NlOc.3. I ,  Pten, and/or ~ 2 7 ~ ' ~ ' ,  Abate-Shen and Shen 
produced models that ultimately progresses through localized adenocarcinoma to invasion and metastases (Kim 
et al., Proc Natl Acad Sci U S  A, 2002; Abate-Shen et al., Cancer Res, 2003). Cancer progression in these mice 
increased with age, and the invasive tumors displayed morphological features highly reminiscent of human 
prostate cancer. Moreover, androgen-ablation led to androgen-independent prostate cancer and distant 
metastases. Thus, depending on the specific gene deletion and age of the mouse examined, these mutant mice 
provide pre-clinical models for studying chemoprevention, angio- and lymphangiogenesis, and for testing new 
chemotherapeutic agents. For example, ongoing studies being conducted in collaboration with DiPaola, 
examine the effectiveness of calcitriol for chemoprevention in mice and man. Other studies are planned to 
investigate the consequences of inhibiting Akt function in the acquisition of an androgen-independent 
phenotype (vide infra). 
Shen is developing new mouse models for tracking tumor growth and metastases using high-resolution imaging. 
This strategy entails generation of a knock-in targeting allele to serves as a permanent imaging marker for 
tracking prostatic epithelial cells, thereby allowing investigators to follow tumor growth as well as emerging 
metastases. These mouse models facilitate studies designed to understand the biology behind tumor invasion, as 
well as the molecular events that allow transformation from androgen-dependent to independent-growth. 
Imaging approaches will enable more efficient drug testing, since they will permit investigators to asses the 
effects of treatment without sacrificing the animals. 
Therefore members of the Prostate Program supported by the GPCC include some of the nation's leaders in 
understanding the molecular changes that underlie the development of normal and abnormal prostatic 
epithelium. They have identified fundamental aspects of signaling pathways and transcription factors whose 
dysfunction may underlie prostate carcinogenesis. Members generated a unique series of models, summarized 
in Table 1 ; these permit investigation of all stages of prostate cancer development and enable investigators to 
study the molecular biology of disease progression. These models are also being used for pre-clinical studies to 
design effective strategies for therapy (Aim 2) and prevention (Aim 3). The Prostate Program recruited basic 
researchers, including those who were not previously involved in disease-based research, to study prostate 
cancer. We anticipate that during the next grant period this work, aimed at analyzing prostate growth and 
development, mechanisms of transcriptional control, and other fimdamental aspects of prostate biology, will 
continue to inform studies on prostate cancer pathophysiology. 
Table 1:. Mouse Models of Prostate Cancer Developed by Program Members 
STAGE 
Preldisposition to 
cancer 
(hyperplasia, 
dysplasia, and low- 
grade PIN) 
Early stages of 
cancer progression 
(high-grade PIN; 
carcinoma in situ) 
Overt carcinoma 
(locally invasive 
adenocarcinoma) 
Advanced disease 
(androgen- 
independence and 
metastases) 
MODELS 
Nkx3.1 mutants 
IGF-BP mutants 
compound mu tan t s ; 
“young” Nkx3.1Pten 
compound mutants 
HMGA2 transgenic 
mice; 
aged %3.1/Pten 
compound mutants 
Androgen-ablated 
Nkx3.1Pten 
compound mutants 
POTENTIAL USES 
Design of new chemoprevention 
approaches; identification of 
prognostic indicators for patients 
at risk for prostate cancer. 
Design of new chemo- 
prevention approaches; 
identification of prognostic 
indicators for early-stage disease 
Design of new anti-cancer drugs; 
identification of pathways of 
progression 
Design of new chemotherapeutic 
approaches; identification of 
molecular correlates that 
distinguish androgen-dependent 
and independent stages of 
disease. 
THERAPEUTIC TRIALS 
PLANNED OR IN PROGRESS 
Effectiveness of green tea for 
preventing prostate cancer 
(planned); role of dietary factors in 
cancer initiation (planned): role of 
oxidative damage in 
carcinogenesis (ongoing). 
Effectiveness of calcitriol in 
cancer prevention (ongoing); 
consequences of androgen- 
signaling for cancer progression 
(ongoing). 
Consequences of using 
combinations of 2-deoxyglucose or 
mTOR inhibitors (planned). 
Androgen-ablation combined with 
mTOR inhibition and/or 2- 
deoxyglucose (planned). 
2. To build on fundamental knowledge to develop effective therapeutic approaches for the treatment of 
prostate cancer. 
RATIONALE/CANCER FOCUS: The Prostate Program strives to develop the biological basis for more effective 
methods of treatment and prevention. Program members design and conduct mechanistic-based clinical trials 
built on both laboratory findings and clinical observations. Members also provide national leadership to 
improve the treatment of prostate cancer. The mechanisms underlying the development of prostate cancer and 
the progression from in situ to invasive disease and then from hormone-sensitive to hormone-resistant disease 
are themes that are being analyzed. Investigators pursued the molecular mechanisms of drug resistance, 
developed strategies to circumvent resistance with early therapy, and used novel approaches to abrogate 
resistance mechanisms. Summarized below are examples of these research accomplishments. 
ACCOMPLISHMENTS: As elegantly demonstrated by many studies in human prostate cancer, as well as the cell 
culture and mutant mouse models described in Aim 1, the development of neoplastic prostate epithelium results 
from progressive alterations of pathways that regulate normal cell growth and differentiation. Program members 
conduct studies in parallel to determine if this progression pathway can provide insights into mechanism of drug 
resistance. For example, William Hait worked with DiPaola to understand the basis for the refractory nature of 
prostate cancer to therapy. The CINJ Tissue Retrieval Service enabled the study of sequential expression of 
drug-resistance gene products in 95 human prostate cancer specimens obtained from patients who had not 
received hormonal treatment or chemotherapy (Sullivan et al., Clin Cancer Res, 1998). As benign glandular 
epithelium progressed through low-stage, low-grade prostate neoplasia to high-grade, high-stage disease, there 
was a serial increase in expression of several determinants of drug resistance. Notably, they found evidence for 
p53 mutations in 15-20% of early prostate cancers that markedly increased with advancing stage and grade of 
disease. In addition, this work suggested that p53 might regulate the expression of determinants of drug 
sensitivity such as topoisomerase 11-a and the multidrug resistance protein gene, MRPl. They went on to show 
that MRPl is transcriptionally regulated by p53 (DiPaola and Aisner, Semin Oncol, 1999; Sullivan et al., J Clin 
Invest, 2000; Yang et al., Mol Cancer Res, 2003) and that MRPl protein decreased accumulation and increased 
efflux of the antiandrogens, but had no effect on dihydrotestosterone accumulation; a posteriori evidence that in 
the face of p53 mutation and MRP overexpression, androgens might reach their receptors but anti-androgens 
might not. These results provided a mechanistic basis for the expectation that the use of chemotherapy late in 
the course of disease would be hampered by a panoply of drug resistance mechanisms and defined a previously 
unexpected mechanism of resistance to both chemotherapy and antiandrogen therapy in prostate cancer patients 
who had received neither form of treatment (DiPaola, Semin Oncol, 1999; Grzywacz et al., Cancer Res, 2003). 
These data and other findings challenged the conventional wisdom that chemotherapy ought be used only after 
hormone ablation, and raised the hypothesis that early chemotherapeutic treatment of prostate cancer may lead 
to better outcomes. Therefore, DiPaola, Goodin and Todd conducted a series of chemotherapy-based clinical 
trials in patients before the initiation of hormonal therapy that included a series of laboratory correlates 
conducted in the DiPaola laboratory funded by several NCI R03 grants (DiPaola et al., Clin Cancer Res, 1997; 
DiPaola, Semin Oncol, 1999; DiPaola et al., J Clin Oncol, 1999; DiPaola et al., Cancer, 2001; Thalasila et al., 
Cancer Chemother Pharmacol, 2003). These investigator-initiated studies focused on patients with progression 
of disease based on increasing PSA who had not received hormonal therapy (Table 2). For example, 
mitoxantrone was studied in this early patients population and p53, bcl-2 and topoisomerase expression was 
assessed in available tumor samples (DiPaola et al., Cancer, 2001). Although the clinical activity of this agent 
was not strikingly different fkom historical data for treatment of more advanced disease, this trial laid the 
groundwork for studies of potentially more active and targeted agents in previously untreated patients. 
Several additional lines of evidence suggested that p53 status may predict sensitivity to chemotherapy. In 
collaboration with Eileen White and Arnold Levine (Molecular Mechanisms of Tumor Growth), the Hait 
laboratory found that the functional status of p53 was closely associated with vinca alkaloid (e.g. vinblastine 
and vincristine) and taxane (e.g. paclitaxel) sensitivity. Whereas cells with wild-type p53 were relatively 
sensitive to vincas and resistant to taxanes, those with mutant p53 showed the opposite profile. They 
demonstrated that the expression of microtubule associated protein 4 (MAP4) was regulated by the 
transcriptional status of p53. Cells with mutant-p53 had increased expression of MAP4, increased 
polymerization of microtubules, and increased binding and sensitivity to taxanes (Zhang et al., Oncogene, 
1998). In related studies, members of the Cancer Pharmacology/ Developmental Therapeutics and Breast 
Cancer Research Programs investigated the activity of epothilone B, a novel microtubule stabilizing agent 
whose transport is not affected by ATP Binding Cassette family transporters such as MRPl or P-glycoprotein. 
DiPaola and White studied p53 status as a marker of sensitivity to epothilone B and demonstrated that this 
microtubule stabilizer was more cytotoxic to cells with mutant p53 (Ioffe et al., Proc Amer Assoc Cancer Res, 
2003), consistent with the observations with taxanes. Based on these findings, DiPaola initiated a study of 
epothilone and estramustine in hormone-refractory prostate cancer (Table 2) and received Cancer Treatment 
Evaluation Program (CTEP)-approval for developing this approach through ECOG. In this study the status of 
p53, MAP4 and MRP will be assayed to determine if they predict sensitivity to epothilones in the clinic. 
DiPaola, Hait and White also demonstrated that overexpression of bcl-2 in model systems developed by the 
White laboratory blocked the collateral sensitivity to taxanes seen in p53 mutant cell lines. Since 
overexpression of bcl-2 had been observed in earlier studies of human prostate cancer specimens, DiPaola 
designed studies to abrogate this antiapoptotic mechanism. He identified cis-retinoic acid and alpha-interferon 
( C W I F N )  as potent bcl-2 modulators that restored the sensitivity to taxanes in cell lines with mutant p53 and 
bcl-2 overexpression. He then carried out translational studies including an initial pilot study of the modulators 
alone in patients with prostate cancer (DiPaola et al., Clin Cancer Res, 1997; DiPaola and Aisner, Semin Oncol, 
1999), followed by a series of phase 1 studies in combination with chemotherapy (DiPuola et ul., J Clin Oncol, 
1999; DiPaola et al., Hematol Oncol Clin North Am, 2001; Thalasila et al., Cancer Chemother Pharmucol, 
2003). These initial trials were funded by two R03 grants to DiPaola (CA77135; CA80654). The use of 
C W I F N  was adopted by ECOG through a phase I1 study of C W I F N  and paclitaxel in patients with 
4 
hormone-refractory prostate cancer (E3899). An additional study based on these early findings is a DOD- 
funded, investigator-initiated trial of retinoic acid, alpha-interferon, taxotere, and estramustine ongoing at CINJ 
(DOD DAMDl7-02- 1-0229, P1:DiPaola). DiPaola's laboratory was the reference laboratory for measuring the 
effects of treatment on bcl-2 and other molecular correlates for the ECOG studies. 
i 
Recently, work by DiPaola and White has resulted in a DOD Idea Grant award (DOD W81XWH-05-1-0036). 
This was based on prior studies that demonstrated the dependence of early tumor growth and progression on 
anaerobic metabolism through glycolysis. In fact, the preference for tumor cells to depend on glycolysis over 
normal cells is the basis for the successful development of FDG-PET imaging. Despite these prior data, clinical 
development of agents that target glycolysis has been limited with initial concern over the lack of a therapeutic 
window. However, more recent studies have demonstrated that abnormal growth factor and apoptotic 
pathways, required by tumor cells to resist multiple insults, can drive tumor cells to even further dependence on 
glycolysis, supporting a rationale for selectivity of abrogating glycolysis in tumor cells compared to normal 
cells. For example, studies have recently demonstrated that activation of Akt kinase, which occurs commonly 
in tumor such as prostate cancer that are PTEN deficient, increases dependence of glycolysis. To test agents 
capable of abrogating the induction of glycolysis, we set up a laboratory co-culture model that could detect the 
growth effect of autocrine stimulation by tumor cells. Using two dimensional (2D) in-gel electrophoresis 
(DIGE) and Mass spectrometry, we found that initial changes consisted exclusively of induction of multiple 
glycolytic enzymes (Dvorzhinski et al., Proteomics, 2004). To determine if specific molecular mechanisms are 
dependent on the induction of glycolysis, we created isogenic cell lines derived from rat prostate epithelial cells 
transformed with both the adenovirus E l A  protein to disrupt RB and a dominant negative form of p53, p53 DD 
(inactivation of RE3 and p53 pathways are sufficient for transformation and immortalization of primary rodent 
epithelial cells) in the laboratory of Dr. E. White. Into this genetic background we have introduced a Bcl-2 
expression vector along with a constitutively active form of Akt, myr-Akt, H-Ras, and IC-Ras. We have already 
began to test 2-deoxyglucose, an inhibitor of glycolysis, and found we could decrease the expression of 
glycoltyic enzymes in the co-culture model, inhibit cell growth at concentrations below what can be obtained 
safely in humans, and have cytotoxicity independent of Bcl-2 overexpression and Akt activation. The co- 
culture model and isogenic cell lines form a basis to continue further laboratory and clinical studies to 
determine the optimal approach to abrogation of glycolysis and mechanisms of sensitivity to such modulation. 
i 
Phase I1 study of 13 cis retinoic 
acid and alpha-interferon 
( C W I F N )  
Table 2. Investigator-Initiated Therapeutic Trials in Prostate Cancer 
1998) 
Completed; 
(DiPaola et al., 
Clin Cancer Res, 
1997) 
TRIAL STATUS LABORATORY BASIS N COLLABORA 
AND CORRELATE TORS 
Early-Stagernormone-Naive Prostate Cancer 
Serum PK activity with androgen 
na7ve patients 
Phase I1 study of mitoxantrone 
Phase I1 study of onconase and 
tamoxifen 
Phase I1 study of Gleevec 
Phase I1 study of pox PSA vaccine 
Phase I1 study of docetaxel 
Completed; 
(Cvijic et al., Clin 
Cancer Res, 2000) 
Completed; 
(DiPaola et al., 
Cancer, 200 1 ) 
Completed; (Eid et 
al. Urol Res, 
200 1) 
Completed; (Rao 
et al. Proc ASCO, 
2003; The 
Prostate, 2004) 
Completed; 
(Kauffman et al. 
Proc ASCO, 2002; 
JCO, 2004) 
Completed; 
(Goodin et al., 
Proc ASCO, 2003, 
JCO in Press) 
AdvancedETormone-Rc 
Phase I study of CRA/IFN 
combined with chemotherapy 
n/a 
Completed; Bcl-2 in peripheral blood 25 E. White, 
(DiPaola et al., J mononuclear cells, PK, DiPaola 
p53, bcl-2, MRP, 
.. 
Phase I study of CRA/IFN 
Serum TGF-beta and IGF- 
1 
Clin Oncol, 1999) P450 evaluation 
Completed; Bcl-2 in peripheral blood 15 E. White, 
PK activity in serum 
combined with weekly paclitaxel 
Phase I study of bcl-2 antisense in 
HWC (PI at MSKCC with 
Zollaboration for lab correlate) 
Phase VI1 study of novel PSA 
activated peptide-doxorubicin 
Bcl-2, p53, and top0 I1 
(Thalasila et al., mononuclear cells DiPaola 
Cancer Rubin 
Chew other 
Pharmacol, 2003) 
Completed; Collaboration with main 20 MSKCC 
(Morris et a]., Clin DiPaola (lab 
Cancer Res, 2002) bcl-2 laboratory studies component) 
Completed; PK of peptide and 30 DiPaola 
(DiPaola et al., J conjugate 
PI at another institution for 
Serum IGF-1 and TGFbeta 
PDGF 
immunohistochemistry 
T-cell immunity 
(ELISPOT) 
Peripheral blood 
mononuclear cell bcl-2 
bactouy Prostate Cancer 
30 
98 
30 
14 
23 
13 
21 
70 
25 
Kumar 
DiPaola 
Weiss 
Hait, Amenta 
DiPaola 
Weiss 
Cummings 
Chen 
DiPaola 
DiPaola, 
Weiss 
Todd 
DiPaola, 
Weiss, Todd 
DiPaola, 
Goodin 
Kaufman, 
DiPaola 
DiPaola 
Weiss 
Goodin 
conjugate 
Phase I study of pox PSARRICOM 
vaccine 
Phase I1 study of docetaxel and 
vinorelbine 
E3 899: A randomized phase I1 
study of CRA/IFN and paclitaxel 
vs. estramustine, mitoxantrone, and 
vinorelbine 
Phase I and I1 study of C W I F N  
combined with estramustine and 
docetaxel (RITE) 
Phase VI1 study of estramustine in 
combination with epothilone 
Phase I1 study of estradiol patch as 
salvage therapy 
Phase I1 study of licorice root 
derivative combined and docetaxel 
Clin Oncol, 2002) 
Completed; 
DiPaola et al., 
Proc AACR. 2004 
Completed: 
Goodin et al., 
Proc ASCO, 2002, 
Ca Chem Pharin 
2005 In Press) 
Completed; 
DiPaola et al., 
Proc ASCO, 2004 
Ongoing: 
Elsyad et al., Proc 
ASCO, 2004 
Completed; 
Wojtowicz et al., 
Proc ASCO, 2004 
Ongoing 
Ongoing 
T-cell immunity 
(ELISPOT) 
Bcl-2 in peripheral blood 
mononuclear cells 
Bcl-2 in peripheral blood 
mononuclear cells, PK, 
PK 
Plasma estrogenicity by 
yeast assay 
Estrogen yeast assays of 
patient serum 
10 
40 
70 
(National) 
10 
15 
11 
DiPaola 
Lattime 
E. White 
DiPaola 
Rubin 
E. White 
Rubin 
Lambert 
DiPaola 
Lambert 
Gallo 
DiPaola 
Although the focus of the Prostate Program is on investigator-initiated, translational research, CINJ members 
are also active participants in ECOG and intergroup trials, as well as cooperative efforts with other cancer 
centers. This work is promulgated by the recent appointment of DiPaola as Chair of the ECOG Genitourinary 
Committee. In this administrative role, DiPaola is responsible for the development of studies within the 
committee, as well as serving as principal investigator on a number of studies. Approved and developing 
studies (in addition to those shown in Table 2) that DiPaola will serve as chair or co-chair include the use of 
epothilone as a salvage therapy in prostate cancer and a randomized phase I11 study of ProstvacTM vaccine in 
combination with GM-CSF in patients with PSA progression after local therapy. The latter is based data from a 
vaccine trial completed through ECOG demonstrating that the optimal vaccine schedule was a “prime and 
boost” approach (E7897, Kaufinan et al., JCO 2004, Proc. ASCO, 2002, DiPaola JCO, 2004). 
DISCUSSION: Program members identified critical determinants of drug sensitivity in human prostate cancer and 
elucidated novel mechanisms of resistance. These studies informed the development of investigator-initiated 
clinical trials designed to counter drug-resistance in patients with prostate cancer. The tremendous growth in 
this area emphasizes the success of this disease-based program in meeting one of the CINJ strategic goals-- 
increasing translational research. However, CINJ also recognized the need for additional strength to 
complement the leadership of DiPaola. Accordingly, CINJ and the Department of Surgery recruited Ronald 
Morton, an nationally-recognized urologist who will head the Division of Urology at RWJMS. In addition, 
CINJ resources were made available to recruit a pathologist to focus on prostate cancer, as well as two medical 
oncologist to work with DiPaola and Todd. Dr. Mark Stein, medical oncologist was recruited to the GU team 
in July of 2004. This team of investigators will capitalize on the new mouse model of prostate progression from 
androgen-dependent to independent disease as preclinical models to investigate new approaches to prevent 
and/or treat this lethal transition. 
3. To improve the control of prostate cancer through early detection, prevention, and information 
i dissemination. 
RATIONALE/CANCER FOCUS: The control of prostate cancer will require more powerful methods of prevention, 
early detection, treatment, and dissemination of new information to populations at risk. A major thrust of the 
CINJ Division of Prevention, Control and Population Science (Carcinogenesis and Chemoprevention; 
Population Science Programs) is to develop effective chemopreventive strategies and apply these to populations 
at risk. Prostate Program members pursue basic research approaches to understand the molecular mechanism 
underlying disease initiation. These studies, as well as pre-clinical studies in mutant mice and cell lines will lead 
to mechanistic based approaches to prevention. The recent recruitment of a cancer epidemiologists who 
investigate screening and surveillance methods (Lu-Yao), as well as the nutritional basis of hormonally-derived 
cancers (Bandera) create a new interface with the Population Science Program. Therefore, the work conducted 
by members of the Prostate Program provides mechanistic basis for new and ongoing cancer control research. 
ACCOMPLISHMENTS: he carcinogenic process often involves oxidative and inflammatory processes. For 
example, Drs. Abate-Shen and Shen recently found that loss-of-function of Nkx3. I led to increased oxidative 
damage to prostatic epithelium as a function of aging. Laskin utilizes rodent models to characterize the effects 
of oxidation on the bioactivation of carcinogens in the prostate (a tissue with limited cytochrome P540 activity) 
and how diet effects this process (Laskin et al., J Toxic01 Environ Health A, 2000; Billack et al., Biochem 
Pharmacol, 2001; Laskin et al., Adv Exp Med Biol, 2001; Ahmad et al., JLeukoc Biol, 2002; Billack et al., Am J 
Physiol Cell Physiol, 2002). He recently received NCI R01 funding to investigate a previously unrecognized 
molecular target for preventive agents in the prostate discovered in collaboration with Diane Heck 
(Carcinogenesis and Chemoprevention). They demonstrated that catalase has dual effects in the prostate 
including the oxidation of carcinogens to DNA-reactive metabolites (Heck et al., J Biol Chem, 2003). They used 
cDNA clones to generate and characterized cell lines that overexpress catalase activity, an enzyme with high 
affinity for major genotoxic chemicals that induce prostate tumors when administered to rodents (3,2'-dimethyl- 
4-arninobiphenyl (DMAB); 2-amino-l-methyl-6-phenyl-imidazo(4,5- b)pyridine (PhP); N-nitrosobis (2- 
oxopropyl) amine and; N-methyl-nitrosourea. PhIP is a heterocyclic amine produced during cooking that has 
only recently been identified as a prostate carcinogen. DMAB, a synthetic aromatic amine, is a member of a 
large family of aminobiphenyls synthesized by the chemical dye industry. The Laskin group went on to show 
that several important nutrients, in particular, ferulic acid, vanillic acid and epigallocatechin gallate, are 
effective and potent inhibitors of the newly discovered role of catalase in the prostate. During the next grant 
period, collaborative efforts are planned to validate this target in mouse models and in human prostate cancer, 
identify more potent and selective inhibitors, and initiate clinical trials to assess the development and 
progression of prostate cancer. 
Paul Copeland recently received R01 funding to investigate selenium metabolism and is applying his work to 
prostate cancer. Dietary supplementation with selenium was reported to decrease total cancer mortality and 
specifically reduced the incidence of lung, colorectal and prostate cancers (Clark et al., JAMA, 1996; Copeland 
and Driscoll, Biofactors, 2001 ; Copeland and Driscoll, Methods Enzyrnol, 2002; Copeland, Gene, 2003). 
Copeland, a recently recruited authority of selenoproteins, hypothesized that increased dietary selenium is either 
acting through the production of selenoproteins or through the action of selenium-containing small molecules 
that have unknown function (Driscoll and Copeland, Annu Rev Nutr, 2003). Since many selenoproteins protect 
against oxidative damage, he is testing the hypothesis that the chemoprotective effect of selenium 
supplementation is through an increase in selenoprotein expression. He reasoned that if increased dietary 
selenium is primarily functioning through the selenoprotein pathway, then prostate cancer cells should have 
altered selenoprotein expression. Indeed, it has been observed that at least one selenoprotein is dramatically 
reduced in prostate cancer. Dr. Copeland is studying the effects of both increased selenium and increased 
selenoprotein synthetic capacity on prostate carcinogenesis in model systems. This work will be greatly 
enhanced through access to the mouse models available to program members. One of the ultimate goals is to 
identify means by which to modulate the efficiency of selenoprotein synthesis, ideally in a selenoprotein- 
specific manner. 
It is estimated that millions of Americans use nutraceuticals for disease treatment and prevention. Among these 
numerous unregulated substances are a host of herbal preparations. DiPaola leads a team of investigators 
interested in the carcinogenic and anticarcinogenic effects of phytoestrogens, with the goal of identifying non- 
toxic agents for chemoprevention. This work began when DiPaola observed that many of his patients were self- 
medicating with PC-SPES, a Chinese herbal concoction that was widely used by men to self-medicate their 
prostate cancer. DiPaola, Hait, Gallo (Carcinogenesis and Chemoprevention) and Lambert described the 
biological actions and toxic side effects of PC-SPES. They demonstrated the presence of potent phytoestrogens 
that were a likely biological explanation for both the activity and side effects of this preparation, and 
emphasized the importance of hrther study of novel estrogens as active clinical agents in prostate cancer 
(DiPaola et al., N Engl JMed, 1998; Marks et al., Urology, 2002). They went on to show that the mixture was 
contaminated with synthetic substances; this eventually led to the banning of PC-SPES from the market (Marks 
et al., Urology, 2002). 
Lambert and DiPaola initiated investigator-initiated clinical trials studying phytoestrogens and pharmaceutical 
estrogens (DiPaola et al., NEngl JMed, 1998; Rafi et al., Anticancer Res, 2000; Zhu et al., JNat  Prod, 2001; 
Zhu et al., Phytochemistry, 2001; Rafi et al., JAgric Food Chem, 2002). They began by testing the safety and 
efficacy of these substances in men with prostate cancer, with the goal of moving active, non-toxic compounds 
into prevention trials for men (e.g. African Americans) at high risk. This paradigm follows the successful 
methods used for tamoxifen in breast cancer. For example, they are studying the activity of licorice root for 
patients with early disease (NCI-funded project), licorice root combined with taxotere for patients with 
hormone-refractory prostate cancer (NCI-funded Pilot Project), and an estradiol patch in men with prostate 
cancer that is refractory to hormonal and chemotherapy (See Tables 2 and 3). In these studies plasma 
estrogenicity will be determined by a yeast reporter system sensitive to activation of both ER alpha and beta. 
Further laboratory studies by DiPaola and collaborators identified additional phytoestrogens from licorice root 
including a novel dihydrophenol (DHP) capable of inducing apoptosis, mitotic arrest, bcl-2 phosphorylation, 
and microtubule bundling, and filed and received patents for this discovery (Rafi et al., JAgric Food Chem, 
2002). Recently, the interaction of DHP with AR was studied by computational modeling in collaboration with 
William Welsh (Cancer Pharmacology/Developmental Therapeutics) (Ai et al., Chem Res Toxicol, 2003). 
These results suggest that DHP could function both as an androgen-receptor antagonist and, unexpectedly, as an 
estrogen-receptor agonist. Drs DiPaola and Welsh are submitted a NCI grant in October 2004 to further 
characterize DHP as a lead compound with potentially “ideal” pharmacological characteristics for the 
prevention or treatment of prostate cancer. 
Robert Weiss in collaboration with C.S. Yang (Carcinogenesis and Chemoprevention) (Yang et al., Annu Rev 
Pharmacol Toxicol, 2002; Ju et al., Nutr Cancer, 2003; Lambert et al., JNutr, 2003), investigates the effects of 
green tea constituents in patients with prostate cancer, through clinical trials supported by GPCC 
Developmental Funds. As part of this trial, concentrations of green tea polyphenols in the prostate are measured 
following a single dose of green tea administered before prostate surgery. 
Members are also beginning to use the mutant mice models described in section 1 (see Table 1) as pre-clinical 
tools to test chemopreventive agents and to follow these results with studies in the clinic. For example, Abate- 
Shen and DiPaola are studying the effects of calcitriol(1,alpha 25, dihydroxy-vitamin D3), a vitamin D 
derivative with antitumor effects in vitro and in vivo. Proposed mechanisms include the modulation of p21, p27, 
and the baxhcl-2 interaction. In clinical studies, calcitriol was shown to slow the rise of PSA in patients with 
prostate cancer and appeared to enhance the anti-tumor effect of platinum compounds and taxanes. Drs. 
DiPaola and Abate-Shen initiated a pre-clinical study in Nkx3. I mutant mice to examine whether calcitriol can 
reduce the incidence of prostate cancer in these mice. Preliminary results support the idea that calcitriol 
prevents the development of high-grade PIN. In parallel, DiPaola is conducting a randomized, trial of calcitriol 
in men with biopsy-proven high-grade PIN (Table 3). Tissue will be assessed before and after treatment to 
evaluate the effects of calcitriol in this high-risk population. High-grade PIN is associated with a 40-50 percent 
' chance of developing prostate cancer. Autopsy series demonstrated that high-grade PIN occurs as early as the 
fourth decade, 'and increases in incidence with age. Therefore, non-toxic agents that reduce this intraepithelial 
neoplasia would be candidates for larger prevention studies. 
N 
NA 
Table 3. Investigator-initiated Prevention Trials in Prostate Cancer 
COLLABORATORS 
Abate-Shen 
DiPaola 
TRIAL 
Phase I1 study of 
calcitriol in patients 
with PIN 
Assessment of 
phytoestrogens in 
PC-SPES in patients 
with androgen nayve 
prostate cancer in 
man and animals 
The effect of soy on 
testosterone and 
PSA 
Phase I1 study of 
licorice-root 
derivative in patients 
with HNPC. 
Assessment of Green 
tea in patients with 
mostate cancer 
STATUS 
Ongoing 
Complete; (DiPaola et 
al., NEngl JMed,  
1998; Marks et al., 
Urology, 2002) 
Complete; (Goodin et 
al,. Proc ASCO 2004) 
Ongoing 
Ongoing 
LABORATORY BASIS AND 
CORRELATES 
Preclinical mouse experiments; 
transcriptional and translational 
profiles. 
Estrogen yeast assays in vitro 
and in vivo mouse experiments 
Serum LH, Test, PSA 
Estrogen yeast assays of patient 
serum 
Tumor chemistry/apoptotic 
markers 
8 DiPaola 
Gallo 
Lambert 
15 
16 
Lambert 
Goodin 
DiPaola 
Lambert 
Gallo 
DiPaola 
C.S. Yang 
Members strive to develop better methods of early detection and to use screening approaches responsibly and 
effectively. For example, Weiss collaborates with Armand Sarveysian to investigate the utility of mechanical 
imaging of the prostate (Perrotti et al., J Urol, 1999; Perrotti et al., Urology, 1999). They developed a device 
that detected nodules in prostate phantoms with a sensitivity exceeding that of an experienced urologist. In 
contrast to digital rectal exam, the results with mechanical examination were independent of the operator's 
experience. Therefore, the system appears to be a promising means of increasing the accurate and reproducible 
detection of abnormalities within the prostate (Urology, 2001). 
The widespread use of PSA testing remains an area of intense investigation. Morton (Muldoon et al., J Rural 
Health, 1996; Witte et al., Urology, 1999; Kim et al., Cancer Res, 2000; Link and Morton, Urol Clin North Am, 
2001) received NCI funding to develop a simple, sensitive technique to monitor PSA. This research is based on 
the fact that PSA testing methods remain both inconvenient and costly when applied to screening. Dr. Morton 
designed a prototype biosensor chip for quantitating blood PSA levels. This chip is an amperometric 
immunosensor, which would form the core of an inexpensive handheld device for measuring PSA at the bedside 
or in the physician's office. A critical goal of this project will be to produce a fusion molecule that shares PSA 
immunoreactivity and glucose oxidase enzymatic activity. This conjugate molecule will compete with PSA at 
the chip surface and thereby couple immune recognition to an easily detectable electrical signal. A device of 
this type should significantly impact the diagnosis and treatment of prostate cancer by lowering the cost and 
broadening the availability of PSA testing for all patients at risk. This is of particular concern given the striking 
racial differences in prostate cancer mortality, which may be attributable to inadequate access to PSA screening 
in medically underserved populations. 
5 Dr. Morton will also collaborate with Grace Lu-Yao, a recently recruited prostate cancer epidemiologist, to 
study the impact of PSA testing on the practice of urology (Lu-Yao et al., J Urol, 1997; Lu-Yao and Yao, 
Lancet, 1997; Lu-Yao et al., Urology, 1999; Lu-Yao et al., Bmj, 2002; Lu-Yao et al., JNutl Cancer Inst, 2003). 
For example, using cancer registry data and intention-to-treat methodologies, Dr. Lu-Yao showed that prostate- 
specific IO-year survival for low-grade cancers was similar after prostatectomy, radiotherapy and conservative 
management, but survival of patients with high-grade cancers was significantly better after prostatectomy. She 
also examined the rates of radical prostatectomy in Medicare beneficiaries before and after the introduction of 
PSA testing. The results showed a rapid increase in radical prostatectomies following the introduction of  PSA 
testing followed by a sharp decline seen particularly in older and white men. A third study examined the 
interval after PSA screening and subsequent risk of incurable prostate cancer. Using men 65 years old or older 
from nine SEER registries, she found that among those diagnosed with prostate cancer, the risk of non-localized 
cancer did not differ between those tested two or three years prior to diagnosis and those tested one year prior to 
diagnosis. However, the rate of prostate biopsy was directly related to the number of PSA tests performed (Yao 
and Lu-Yao, J Urol, 2001). Dr. Lu-Yao used SEER and Medicare data to compare rates of screening, treatment 
and mortality. These data showed that higher rates of PSA screening, prostate biopsy, radical prostatectomy, 
and external beam radiotherapy did not affect the adjusted mortality odds ratios in elderly patient populations 
(Lu-Yao et al., Bmj, 2002). In a recent report, Dr. Lu-Yao investigated the use of PSA screening in elderly men 
(Lu-Yao et al., JNatl Cancer Inst, 2003). By using a nationally representative sample of 7889 men who 
participated in the 2000 National Health Interview Survey, she found that the rate of PSA screening among men 
aged 75 or older was 32.5%, which was greater than that of fecal occult blood screening among men despite 
lack of evidence suggesting a benefit in this elderly population. 
Lu-Yao also investigates the utility of radical prostatectomies in elderly patients. She used Medicare claims 
from 1991 to 1994 to identify and quantify the types and risks of complications, re-hospitalization within 90 
days, and mortality at 30 and 90 days after perineal or retropubic prostatectomy. On the basis of data from 
101,604 men, they found that complications and readmission after prostatectomy are substantially more 
common than previously recognized, and that older age is associated with elevated surgical mortality and 
complications (Lu-Yao et al., Urology, 1999). 
The work of Lu-Yao and Morton will be of critical importance to that of Mrs. Betty Gallo, a leading prostate 
cancer advocate. An important goal of the Prostate Program is to develop effective strategies for outreach into 
the community. This has been initiated through involvement of prostate cancer advocates under the tireless 
leadership of Gallo, who established strong ties with the minority community through the 100 Black Men 
organization and the Men's Health Network. These efforts include education and screening programs for the 
African American community, and will provide access to this population for the epidemiological and 
intervention studies. Ms. Gallo sits on the CINJ protocol review and monitoring committee to ensure the 
interests of the survivor and advocacy communi ties are represented. 
A major goal of the Gallo Prostate Cancer Center (GPCC) Cancer Control and Education Program is the 
reduction of prostate cancer incidence, morbidity and mortality among the residents of the State of New Jersey. 
GPCC focused on cancer control including the education of the public in the State of New Jersey about early 
detection of prostate cancer, particularly the Ahcan  community where the need and the risk are both the 
greatest and the study of novel mechanisms to improve education through understanding aspects of culture 
diversity. The only available treatments for prostate cancer that are curative require the identification of the 
disease at these early stages of its development. In order to achieve these goals a pilot project award was given 
to the 100 Black Men of New Jersey and the Men's Health Network (MHN), Washington, D.C. New Jersey 
ranks number 1 in per capita incidences of prostate cancer in the United States according to the American 
Cancer Society, Cancer Facts and Figures, 2003. In 1999 the Gallo Prostate Cancer Center in collaboration 
with the 100 Black Men of New Jersey, initiated a program to offer free prostate cancer education and 
screenings to African-Americans in New Jersey. Congressman Donald Payne and Congressman Robert 
Menendez collaborated with the center to initiate the education and screening program. The program was 
started in Essex County of New Jersey who has the highest incidence rate of prostate cancer in African- 
* Americans in the state. The increase of awareness of prostate cancer was achieved through several 
mechanisms: i. Providing opportunity for more public education and screenings, ii. Preparing and distributing 
brochures to a variety of community places such as barber shops and churches, iii. Increasing our current 
outreach efforts to include not only African-Americans but also the male population as a whole. In 1999 there 
were no educational materials available for the African-American or Latino community about prostate cancer. 
In our collaboration with the 100 Black Men of New Jersey and the Men's Health Network the center developed 
culturally sensitive materials for these communities with specific information about that communities incidence 
rate (brochures attached). These materials were distributed at health fairs, Village Gatherings in underserved 
population areas, mostly intercity (organized by the 100 Black Men of New Jersey) and prostate cancer 
education and screening programs as well as distributed to other outreach programs at local hospitals including 
the Partners and Affiliate Network of the Cancer Institute of New Jersey. The Men's Health Network's primary 
goal is education and awareness about men's health issues. The program with the MHN has advanced the 
awareness of prostate cancer on a national and international level. 
DISCUSSION: Members identified new mechanism of carcinogen activation, providing new targets for screening 
and prevention. The also developed new imaging technologies and critically assessed the widespread use of 
PSA testing. Although the Prostate Program is new, it has already acquired significant expertise in prevention 
and control research. Promising areas of research include the use of mouse models for discovery of 
carcinogenic substances, for identifying important new targets for chemoprevention, understanding the function 
of selenium and selenoproteins, and innovative work on herbal substances. Access to healthy patient 
populations for preventive trials will be greatly enhanced by the recruitment of Morton, who will expand the 
Urology service, and the arrival of epidemiologists to take advantage of the strong ties with the African 
American community. Morton, has considerable experience in the training and dissemination of information to 
minority communities, thereby providing an even stronger link to the outreach and advocacy work of Gallo. 
Future Development 
The Prostate Program is built on a strong foundation of laboratory, clinical, and population research. The 
models developed by program members are all very new; they will be extensively utilized for generating new 
hypotheses for translational studies. Several examples include the use of calcitriol in mouse models, the work 
on phytoestrogens, and the targeting of local activation of carcinogens in prostate tissue: The addition of high- 
resolution small animal imaging studies in collaboration with Jeffrey and Deborah Lasking (Cytokines, 
Cytokine Signaling, and Cancer) will improve the pre-clinical studies using these mutant programmatic 
collaborations. The appointment of DiPaola to the ECOG leadership will accelerate translation of many of the 
concepts developed by Prostate Program members. The ability to leverage CINJ Development Funds created a 
robust pilot project activity that will bring additional investigators into the field of prostate cancer research. 
Finally, the arrival of Grace Lu-Yao, Mark Stein and Ronald Morton as well as the recruitment of additional 
members with expertise in medical and surgical oncology and pathology will help the program build strong 
relationships with the Prevntion, Control, and Population Science and with the Clinical Science Division of 
CINJ. 
* 
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EDUCATIONAL PROGRAMS 
FOR RESEARCHERS 
As part of the DOE grant award the center established an education program for the basic and clinical 
researchers. This program included presentations by prostate cancer researchers from UMDNJ and Rutgers 
University interested in prostate cancer research and invited speakers who are experts in prostate cancer in order 
to initiate collaborations among prostate cancer researchers. 
The GPCC Research Working Groups brought together researchers from the two universities interested in 
prostate cancer to present their work and encourage collaborations. Presentations were given by UMDNJ and 
RU prostate cancer researchers. The twenty programs presented can be found in attachment 1. 
On October 9, 1999 the center sponsored their first educational workshop entitled "The Disease and the 
Dilemma" A Workshop on Prostate Cancer". Dr. Leland Chung, Professor of Urology, University of Virginia 
was the invited speaker. UMDNJ and Rutgers University researchers also presented their research. The 
program can be found as attachment 2. 
The center sponsored a retreat on December 8,2001 in which 13 investigators participated by presenting their 
research on prostate cancer. The topics ranged from a discussion of clinical trials to basic studies on prostate 
development. The program is attachment 3. 
A Prostate Cancer Workshop was held on April 24,2002 as part of the CINJ state-wide cancer retreat in 
Princeton, New Jersey. Outside lecturers as well as UMDNJ and RU reseachers were invited to share their 
research findings with the New Jersey researchers. Invited speakers were Dr. Philip Kantoff, Director, The 
Lank Center for Genitourinary Oncology and Associate Professor of Medicine at Dana-Farber Cancer Institute; 
Dr. Angel DeMarzo, Assistant Professor of Pathology at John Hopkins Medical Institutions and Dr. Gerald 
Cunha, Professor of Anatomy and Urology at University of California at San Francisco. The program is 
attachment 4. 
Invited Lecturers: 
Norman M. Greenberg, Ph.D. 
Scott Department of Urology 
Baylor College of Medicine 
"TRAMP: A Transgenic Mouse Model for Prostate Cancer Research I' 
October 18,2000 
Dr. Charles (Snuffy) Myers 
Professor of Medicine and Urology at the University of Virginia 
"Who is at Risk for Hormone-resistent Disease 
May 10,2002 
Simon Cherry, Ph.D. 
UCSD 
"Technologies for In Vivo Imaging of Mouse Models of Cancer" 
December 1 1,2003 
' Attachment 1 
GPCC Research Working Group Lectures 
November 18, 1999 Dr. Eileen White 
Prostate Cancer Apoptosis 
April 6,2000 Dr. John Pintar 
May 4,2000 Dr. Longqin Hu 
"Design of Anticancer Prodrugs for Site-Specific Activation" 
June 1,2000 Dr. K.V. Chin 
"Analystis of Drug Resistance by cDNA Microanray and 
Exo-PKA Activity in Prostate Cancer" 
July 6,2000 Dr. Deidre Nelson 
"Prostate Cell Apoptosis: Regulators and Effectors" 
September 7,2000 Dr. Arnold Rabson 
"A Role for NF-kappaB Activation in Prostate Cancer" 
October 5,2000 Dr. Robert DiPaola 
"Novel Clinical Approaches in Prostate Cancer" 
November 2,2000 Dr. Ramsey Foty 
"Putting the Squeeze on Cancer" A Novel Approach to the Study 
of Malignant Invasion" 
December 7,2000 Dr. Stuart Lutzker 
Cell-cycle Check Pints in Prostate Cancer Cells" 
January 4,2001 Dr. Longhua Li 
"Understanding Tumor Suppressor Gene Involvement during 
Breast Cancer Development on a Genome-Scale" 
February 1,200 1 Dr. Jeffrey Laskin 
"Mechanisms in Photochemotherapy" 
March 1,2001 Dr. Robert Weiss 
"Mechanical Imaging of Prostate: A Novel Means of Prostate 
Examination 
April 5, 2001 Dr. Keith Bupp 
YJse of Random Display Envelope Libraries to Target 
Retroviruses to Specific Cell Types" 
Attachment 1 continued 
October 4,2001 
November 1,2001 
December 6,2001 
January 3,2002 
March 7,2002 
April 4,2002 
May 2,2002 
Dr. Robert DiPaola 
"Targeting Apoptosis in Prostate Cancer" 
Dr. Deidre Nelson 
"Differential Short Versus Long-term Protection of Transformed Rate Prostate Cells to 
Chemotherapeutic Drug-Induced Apoptosis by Bcl-2 and Eib 19K" 
Dr. Robert Weiss 
"The Role of Green Tea in Prostate Cancer 
Dr. Lonqin Hu 
"Design of Anticancer Prodrugs for Site-Specific Activation" 
Dr. John Pintar 
"Genetic Studies of IGFBP Deficient Mice" 
Dr. Stuart Lutzker 
"The Mitotic Checkpoint and Senstivity of Proostate Cancer Cells to Antimicrotubule 
Drugs" 
Dr. C.S. Yang 
"Nutrition and Prostate Cancer'' 
Attachment 2 
The Disease and the Dilemma: A Workshop on Prostate Cancer 
October 9, 1999 
9:OO 
9:30 
10:45 
11:30 
12:15 
l:oo 
2:oo 
2:45 
Welcoming Remarks 
Dr. William N. Hait 
Dr. Steven Ward 
Keynote Address 
Dr. Leland Chung 
Professor of Urology 
University of Virginia 
Prostate Development and Its Relationship to Carcinoma 
Dr. Michael M. Shen 
Molecular Biology of the Normal and Abnormal Prostate 
Dr. Cory Abate-Shen 
Hormonal Mechanisms of Prostate Carcinogenesis 
Dr. Michael A. Gallo 
Lunch 
Prostate Cancer: A Urologist Perspective 
Dr. Kenneth Cummings 
Clinical Approaches to Treating Prostate Cancer 
Dr. Robert DiPaola 
3:30 Closing Remarks 
Attachment 3 
GPCC Scientific Retreat 
December 8,2001 
8:30 Dr. Cory Abate-Shen 
8:35 Dr. Robert DiPaola 
8:50 Dr. Parvesh Kumar 
9:05 Dr. Tamara Minko 
9:20 Dr. Steve Marcella 
9:35 Dr. Carlos Molina 
9:50 Dr. Keith Bupp 
10:05 Dr. Stuart Lutzker 
10:20 Dr. John Pintar 
10:35 Dr. Arnold Rabson 
10:50 Dr. William Hait 
Introduction 
Translational Research in Prostate Cancer 
A Novel Therapeutic Strategy Testing the Safety and 
Feasibility of Concurrent Docetaxel and 3-D Conformal Radiation 
Therapy in patients with High-Risk Locaized Adenocarcinoma of the 
Prostate: Progress Report of an On-going Phase VI1 Trial 
Enhancing the Efficacy of Chemotherapeutic Drug 
by the Suppresssion of Antipoptotic Cellular 
Defense 
PSA Screening and Prostate Cancer Mortality: 
Preliminary Evidence of Increased Incidence of 
Prostatism in Clinically Aggressive Prostate Cancer 
Regulation of the Transcriptional Repressor 
Inducible CAMP Early Repressor in Prostate Cancer 
Cells 
Targeting Retrovirus Using random Display 
Envelope Libraries 
Abrogation of the Mitotic Spindle-checkpoint in 
Prostate Cancer Cells and Sensitivity to 
Antimicrotubule Drugs 
Searching for Prostate Abnormalities in IGFBP KO 
Mice 
Mechanisms of Consitutive NF-kB Activation in 
Human Prostate Cancer Cells 
Molecular Determinants of Response to Therapy in 
Patients with Prostate Cancer 
I 
Attachment 3 continued 
11:05 Dr. Zui Pan Ca2+ Signaling and Bax Translocation in Apoptosis 
of Prostate Cancer Cell Lines 
11:20 Dr. Michael Shen Molecular Determinants of Response to Therapy in 
Patients with Prostate Cancer 
11:35 Dr. Cory Abate-Shen Cooperativity of Tissue-Specific and Broad- 
Spectrum Tumor Suppressor Genes in a Mouse 
Model of Prostate Cancer 
. 
' Attachment 4 
The Dean and Betty Gallo Prostate Cancer Center Symposium 
April 24,2002 
Chairs: Drs. Cory Abate-Shen and Dr. Robert DiPaola 
2:OO Dr. Gerald Cunha Tissue Recombinant Models of Prostateic Carcinogeneis 
2:40 Dr. M. Kim Use Models of Prostate Cancer Initiation and Progression 
3:OO Dr. Philip Kantoff Clinical Progress in Prostate Cancer 
3:40 Dr. K. Rao Characterization of a Novel Prostate Specific Antigen 
Activated Peptide Doxorubicin Conjugate in Patients with Prostate Cancer 
4:OO Dr. Angelo DeMarzo Prostate Cancer: Precursors and Pathobiology 
4:40 Dr. Deidre Nelson Differential Short- Verus Long-Term Protection by BCL-2 
and ElB19K on Transformed Rate Prostate Cells to 
Chemotherapeutic Drug-Induced Apoptosis 
5:OO Dr. M. Fredericks The MAPK Pathway Directs the Proteasomal Degredation 
of Inducible CAMP Early Repressor During the Cell Cycle 
of Prostate Cancer Cells 
5:20 Dr. Junghan Suh Mechanisms of Constitutive NF-kB Activation in Human 
Prostate Cancer Cells 
L 
E 
Co-Leaders: Cory Abate-Shen, Ph.D. 
Robert S. DiPaola, M.D. 
Dr. Cory Abate-Shen Publications: 
Bhatia-Guar, R. Donjacour, A.A., Sciavolino, P.J., Kim, M., Desai, N., Young, P., Norton, C., Gridley, T., 
Cardiff, R.D., Cunha, G.R., Abate-Shen, C. and Shen, M.M. (1999). Roles for Nkx3.1 in prostate development 
and cancer. Genes Dev. 13:966-977. 
Kim, M., Cardiff, R., Desai, N., Banach-Petrosky, W., Parsons, R., Shen, M. and Abate-Shen, C. (2002). 
Cooperativity of Nkx3.1 and Pten loss-of-function in a mouse model of prostate carcinogenesis. Proc. Nutl. 
Acad. Sci. USA 99:2884-2889. 
Kim, M., Bhatia-Gaur, R., Banach-Petrosky, W., Desai, N., Wang, Y., Hayward, S., Cunha, G., Cardiff, R., 
Shen, M. and Abate-Shen, C. (2002). N h 3 .  I mutant mice recapitulate early stages of prostate carcinogenesis. 
Cancer Research 62:2999-3004. 
Park, J.H., Walls, J.E., Galvez, J.J., Kim, M., Abate-Shen, C., Shen, M. and Cardiff, R.D. (2002). Prostatic 
Intraepithelial Neoplasia In Genetically Engineered Mice. Am. J. Path. 161 :727-735 
Abate-Shen, C. and Shen, M. (2000). Molecular genetics of prostate cancer. Genes Dev. 14:2410-2434. 
Abate-Shen, C. and Shen, M.M. (2002). Mouse models of prostate carcinogenesis. Trends Genet. 18, ( 5 )  S 1-S5 
(online). 
Abate-Shen, C. (2002). Deregulated homeobox gene expression in cancer: cause or consequence? Nature 
Reviews Cancer 2:777-85. 
Kim, M., Bhatia-Gaur, R., Desai, N., Cardiff, R.D., Shen, M.M. and Abate-Shen, C. (2000). Mouse models of 
prostate cancer based on NKX3. I mutant mice. American Association for Cancer Research, Annual Meeting, San 
Francisco, CA. 
Abate-Shen, C., Kim, M., Desai, N., Banach-Petrosky, W., Cardiff, R. and Shen, M.M. (2002). Mouse models 
of prostate cancer initiation and progression. American Association for Cancer Research, Annual Meeting, San 
Francisco, CA. 
Abate-Shen, C., Kim, M., Ouyang, X., Gao, H., Banach-Petrosky, W., Sun, X., Cardiff, R. and Shen, M.M. 
(2002). Mouse models of prostate cancer initiation and progression. Cold Spring Harbor Meeting on Mouse 
Molecular Genetics, Cold Spring Harbor, NY. 
b 
Dr. Cory Abate Shen Presentations: 
1999 US-Japan Program Workshop on Developmental Regulators and Cancer, Maui HI 
NIH, Departments of Urology and Pathology, Bethesda MD 
Distinguished Lecture Series, Wistar Institute, PA 
U.C. Davis Cancer Center Seminar Series, Davis, CA 
2000 American Association for Cancer Research Special Conference, Transcription Factor Pathogenesis of 
Jonsson Cancer Comprehensive Center, Prostate Cancer Seminar Series, University of California, 
MD Anderson Cancer Center, University of Texas, Houston TX 
Max Delbruck Center for Molecular Medicine, Berlin, Germany 
German Cancer Research Center, Heidelberg, Germany 
Mouse Models of Human Cancer Consortium, Chantilly, VA 
SPORE grant program Annual Meeting, Chantilly, VA 
Pre-clinical Models in Prostate Cancer Research, Houston, TX 
Cancer at the Millennium, Dana Point CA 
Los Angeles CA 
2001 Symposium Organizer, Annual Meeting of the American Association for Cancer Research, New 
NCVMouse Models of Human Cancer Consortium Satellite Meeting on Preclinical Trials, Bethesda 
Skirball Institute, New York University, New York, N Y  
MD Anderson Cancer Center, University of Texas, Houston, TX 
Mouse Models of Human Cancer Consortium Steering Committee Meeting, San Francisco, CA 
UCSF Mini-Symposium on Mouse Models of Angiogenesis, San Francisco, CA 
Meeting Organizer, Mouse Models of Prostate Cancer, Bar Harbor, MI 
Orleans, LA 
MD 
2002 Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah 
Mouse Models of Human Cancer Consortium Steering Committee Meeting, Boston, MA 
Chair and Invited Speaker, Cold Spring Harbor Meeting on Mouse Molecular Genetics, Cold Spring 
gth Prouts Neck Meeting on Prostate Cancer, Prouts Neck, ME 
First Joint Meeting of the Mouse Models of Human Cancers Consortium (MMHCC) and the Prostate 
Harbor, NY 
SPORES, Bethesda, MD 
.,. , c. 
Dr. Robert S. DiPaola Publications: 
DiPaola R.S., Aisner J. Overcoming bcl-2 and p53 mediated resistance in Prostate 
Cancer. Seminars of Oncology, 26: 112-1 16, 1999. 
DiPaola R.S., Rafi M., Vyas V., Gupta E., Toppmeyer D., Rubin Eric, Patel G., Goodin S., Medina P., Zamek R., 
Zhang C., White E., Hait W.N. Phase I clinical and pharmacologic study of 13-cis retinoic acid, alpha interferon 
and paclitaxel in patients with prostate cancer and other advanced malignancies. J Clin Oncol 17:22 13-22 18, 1999. 
DiPaola, R.S. Approaches to the treatment of patients with hormone sensitive prostate cancer. Seminars of 
Oncology 26:24-27, 1999. 
Rafi M.M., Rosen R.T., Vassil A., Ho C., Zhang H., Ghai G., Lambert G', Hait W.N., DiPaola R.S. Modulation of 
bcl-2 and Cytotoxicity by Licochalcone-A, a novel estrogenic flavonoid. Anticancer Research, 20:2653-2658, 
2000. 
Goodin S., DiPaola RS. Complementary and Alternative Medicine in Prostate Cancer: A Scientific Rationale? 
Highlights in Oncology Practice 18(3):72-76,2000. 
DiPaola R.S., P. Kumar, W.N. Hait, and R. Weiss. State of the Art Treatment and research in Prostate Cancer. 
New Jersey Medicine, 2:23-34,2001. 
Eid J.E., Brunner M., Segal L., Cummings K.B., Weiss R.E., Goodin S., Todd M., Aisner J., DiPaola R.S. Effect 
of P-30 Protein and Tamoxifen on TGF-Beta1 and IGF-1 in Patients with Prostate Cancer, Urologic Oncology 
6:243-247, 2001. 
DiPaola RS, Chenven ES, Shih WJ, Lin Y ,  Amenta P, Goodin S, Shumate A, Rafi MM, Capanna T, Cardiella M, 
Cummings KB, Aisner J., Todd M. Mitoxantrone in patients with prostate specific antigen progression after local 
therapy for prostate cancer. Cancer. 2001 Oct 15;92(8):2065-71. 
DiPaola R.S., Patel J., Rafi M.M. Targeting Apoptosis in Prostate Cancer. Hematology/Oncology Clinics of North 
America. 15:3:509-524, 2001. 
Rafi MM, Vastano BC, Ho C-T, Ghai G, Rosen RT, and DiPaola RS. Novel polyphenol molecule isolated from 
licorice root (glycrrhiza glabra) induces apoptosis, G2/M cell cycle arrest, and bcl-2 phosphorylation in tumor cell 
lines. J. Agric and Food Chemistry 50:677-684,2002. 
DiPaola RS, Rinehart J, Nemunaiti J, Effinghaus S, Rubin E, Capanna T, Ciardella M, Fontaine M, Adams N, 
Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao S. Characterization of a novel prostate 
specific antigen activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol. 2002 Apr 
1 ;20(7): 1874-1 879. 
S. Goodin, K. Rao, and R.S. DiPaola. State of the Art Therapies in Prostate Cancer. Oncologist 360-70, 2002. 
DiPaola RS. To Arrest or not G2-M cell cycle arrest. The Biology Behind. Clin Cancer Res, 331 1-4, 2002. 
Thalasila, A., Poplin, E., Shih, J., Dvorzhinski, D., Capanna, T., Doyle-Lindrud, S., Beers, S., Goodin, S., Rubin, 
E., and DiPaola, R. S. A phase I trial of weekly paclitaxel, 13- cis-retinoic acid, and interferon alpha in patients 
with prostate cancer and other advanced malignancies. Cancer Chemother Pharmacol, 52; 1 19-124,2003, 
1 
2 DiPaola, R. Durivage, H. and Kamen, B. High time for low-dose prospective clinical trials. Cancer, 98: 1559-1561, 
2003. 
Yao, S. L. and DiPaola, R. S. An evidence-based approach to prostate cancer follow-up. Semin Oncol, 30: 390- 
400,2003. 
Dmitri. Dvorzhinski, Anu. Thalasila, Paul. Thomas, Diedra. Nelson, Hong Li, Eileen. White, Robert S. DiPaola. 
A novel proteomic co-culture model of prostate cancer cell growth. Proteomics. 4:3268-3275, 2004. 
Dr. Robert S. DiPaola Presentations: 
1999 
NOVEL THERAPIES IN CANCER OF THE PR0STATE:TARGETING BCL-2, Cancer Center Grand 
Rounds, University of Pennsylvania, Philadelphia PA, 1/99. 
NOVEL THERAPY FOR PROSTATE CANCER, Seminar, University of Oklahoma, 2/99. 
MODULATION OF PACLITAXEL CHEMOTHERAPY, Combined Medical and Radiation Oncology 
Grand Rounds, New York University, 3/17/99. 
A UNIQUE PERSPECTIVE IN THE TREATMENT OF PATIENTS WITH HORMONE SENSITIVE 
PROSTATE CANCER, Univ of Chicago, taxotere seminar,4/27/99 
PROSTATE CANCER, Grand Rounds, St.Vincent’s Hospital, Staten Island, 5/6/99 
NOVEL THERAPIES FOR PROSTATE CANCER, Oncology Grand Rounds, St. Elizabeth Hospital. NJ, 
5/13/99 
WEEKLY TAXOL/RETINOID/INTERFERON IN PROSTATE CANCER, MD Anderson W.I.S.E. 
conference, NY Palace Hotel, N Y ,  12/18/ 1999 
2000 
TAXOL/RETINOID/INTERERON FOR HORMONE REFRACTORY PROSTATE CANCER, Fox 
Chase Investigators Meeting, Mandalay Bay, Lanai, 3/16/2000 
THE ROLE OF CHEMOTHERAPY FOR PROSTATE CANCER, BMS Symposia, Las Vegas, 312000 
ASCO UPDATE ON PROSTATE CANCER, BMS Symposia, Las Vegas Nevada, 6/30/2000 
NOVEL THERAPY IN PROSTATE CANCER, Medical Oncology Symposia, Seattle WA. 8/10/2000 
RETINOID, INTERFERON AND TAXOL RANDOMIZED AGAINST ESTRAMUSTINE, 
NAVELBINE, AND MITOXANTRONE, Glaxo Advisory Board, Denver CO, 8/25/2000 
OVERVIEW OF PROSTATE CANCER, Distinguished lecture, Brookdale Medical Center, NY, 9/6/2000 
AVENTIS ADVISORY BOARD MEETING, Lake Tahoe Nevada, 9//19/2000 
-2 i 
NOVEL ESTROGENS 
9/24/2000 
PROSTATE CANCER 
10/6/2000 
IN PROSTATE CANCER, CAPCURE SYMPOSIA, Lake Tahoe Nevada, 
OVERVIEW, Medical Oncology Symposia, Intercontinental Hotel, Chicago, 
PC-SPES IN PROSTATE CANCER, THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY 
(ASTRO) SPECIAL SESSION LECTURE, Boston MA, 10/23/2000 
2001 
UPDATE ON THERAPY FOR HRPC, Aventis advisory board, NY NY,  3/8/2001 
AACR SESSION: PROSTATE CANCER OF MICE AND MEN: Chairman, New Orleans, LO 3/25/2001 
TRANSLATIONAL APPROACHES IN PROSTATE CANCER, Oncology Grand Rounds at Dana Farber, 
Boston MA, 4/19/2001 
A PSA ACTIVATED PRODRUG IN HRPC, MERCK ADVISORY BOARD, San Fran, CA, 5/11/2001 
EFFECT OF ESTROGENS IN PROSTATE CANCER, Symposia on Genes and the Environment, 
NATIONAL ACADEMY OF SCIENCES, Washington DC, 5/17/2001 
PC-SPES and prostate cancer, NATIONAL PROSTATE SYMPOSIA (NMCR): WASHINGTON DC, 
5/26/2001 
Treatment for stage D2 prostate cancer, NATIONAL PROSTATE SYMPOSIA (NMCR): Marriott Eastside 
NY, NY, 7/28/2001 
Chairman of session and lecture on Estrogens and Prostate cancer, GORDON CONFERENCE, NH, 
7/8/2001 
State of the art treatment of hormone refractory prostate cancer, MAY0 CLINIC SYMPOSIA, Amelia 
Island, FL 8/16/2001 
Treatment for stage D2 prostate cancer, NATIONAL PROSTATE SYMPOSIA (NMCR): CHICAGO, 
8/25/2001 
Phytoestrogens in prostate cancer, CAPCURE Lecture, Lake Tahoe, 9/9/2001. 
Lecture “Hormone refractory prostate cancer”, NMCR Prostate Symposia, Dallas TX, 9/292001 
Lecture on chemotherapy in prostate cancer. NMCR prostate symposia, Vegas, 1 1/3/2001 
AMERICAN SOCIETY OF RADIATION ONCOLOGY (ASTRO), Special lecture. Complimentary 
medicine in Prostate cancer, 1 1/6/2001. 
2002 
NOCR SYMPOSIA ON PROSTATE CANCER, Atlanta Georgia, 2/12/2002. 
;+“ 
*’ “ ONCOLOGY SYMPOSIA ON BLADDER AND PROSTATE CANCER, Las Vegas NV, 2/24/2002 
CYTOTOXIC CHEMOTHERAPY IN HRPC, Biltmore, Miami, 3/23/2002. 
NOVEL APPROACHES IN PROSTATE CANCER: Medical Grand Rounds at Graduate Hospital, 
Philadelphia, 5/8/2002. 
Presentation on PSA VACCINIA/FOWLPOX VACCINE WITH AND WITHOUT G-CSF FOR 
PATIENTS WITHS STAGE DO PROSTATE CANCER (ECOG 5800) at Therion Advisory Board 
meeting, Orlando FL, 5/17/2002. 
NMCR SYMPOSIA ON PROSTATE CANCER, NY, NY,  6/14/02 
ASCO HIGHLIGHTS IN GU ONCOLOGY, San Diego CA, 6/30/02 
CYTOTOXIC THERAPY IN PROSTATE CANCER, IPCME, St Petersburg FL, 7/12/02 
PROSTATE SYMPOSIA, NMCR, Inverness CO, 7/26/02 
NCI PSA VACCINE WORKING GROUP, Bethesda MD, 7/19 
NCI WORKING GROUP ON RESEARCH WITH PC-SPES, Bethesda MD, 8/12/02 
2003 
AVENTIS ADVISORY BOARD, Prostate Cancer and Bcl-2, 1/03 
MONTEFIORE SYMPOSIA LECTURE ON PROSTATE CANCER, NY, 6/03 
TRANSLATIONAL RESEARCH IN PROSTATE CANCER: Jefferson Medical Center, Urology 
distinguished Lecture 2/03. 
PROSTATE CANCER THERAPY: July, 18, 2003, Invited Speaker,. “ASCO highlights” Network for 
Medical Communication and Research, Las Vegas, NV. 
December 18, 2003, Invited Speaker, “Amonafide Investigators Meeting”, Chicago, IL. 
OVERVIEW OF THERAPY FOR GU CANCER AT ASCO 2003. July 26,2003, Invited Speaker, “ASCO 
highlights” Network for Medical Communication and Research, Hyatt Regency La Jolla, San Diego, CA. 
ASCO 2003. August 9, 2003, Invited Speaker, “ASCO highlights Genitourinary Ma1ignancy”Network for 
Medical Communication and Research, New York, NY.  
August 25, 2003, Invited Speaker by NCI “Prostate Vaccine Program” Marriott Pookshill, Bethesda, 
Maryland. 
I 
September 19-20 2003, Invited Speaker, “Challenging Cases in Prostate Cancer”Network for Medical 
Communication and Research, Chicago, IL. 
September 25, 2003 Grand Rounds, Invited Speaker, “High Risk prostate Cancer”, Stony Brook University 
Hospital, Stonybrook NY. 
&+4! 
October 3,2003 Invited Speaker, MSKCC “ECOG Prostate Debate” - New York Westin Hotel, New York, 
NY. 
b ‘  
October 4,2003, Invited Speaker, “CTEP’s studies of PROSTVAC and PANVAC”, Therion Biologic, The 
Crowne Plaza Hotel, Times 
2004 
February 19-20, 2004, Invited Speaker “Genitourinary Cancer” 1 Oth Annual Meeting, NMCR Educational 
Symposia, Las Vegas, NV. 
FUTURE OF SYSTEMIC THERAPY IN PROSTATE CANCER: ASCO 2004 EDUCATIONAL 
SESSION, New Orleans. 
July 2004. American College of Surgeons (ACOSOG), GU session “ECOG GU trials agenda”, Chicago. 
June 22-23, 2004, Invited Speaker, “ASCO review” - Columbus Community Clinical Oncology Program, 
Columbus, Ohio. 
TRANSLATIONAL GU SYMPOSIA “GENITOURINARY MALIGNANCIES:BENCH, BEDSIDE, 
AND COOPERATIVE GROUPS” June 24-25,2004, Invited Speaker, The University of Iowa College of 
Medicine, Iowa City, IA. 
September 18,2004. Invited Speaker, Future of Prostate Cancer: Urology/Medical oncology symposia on 
developing plans to increase Cooperative Group trial accrual. Four Seasons, Chicago. 
